Nutriband Inc.

NTRB

US67092M2089

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 04:30:00 2024-05-01 pm EDT			5-day change	1st Jan Change
3.5 ^USD	+1.16%		-9.09%	+50.86%

Apr. 24	Nutriband Inc. Closes $8.4 Million Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission	CI
Apr. 23	Nutriband Inc. announced that it expects to receive $8.4 million in funding	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Nutriband Inc.

Nutriband Inc. Closes $8.4 Million Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission	Apr. 24	CI
Nutriband Inc. announced that it expects to receive $8.4 million in funding	Apr. 22	CI
Nutriband Inc. Receives First Order from Fit for Life Group	Apr. 01	CI
Nutriband Inc. Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch	Mar. 27	CI
Nutriband Inc. Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented At 2024 American Academy of Pain Medicine Annual Meeting	Mar. 25	CI
Nutriband Inc. Announces Data on the Incidence of Transdermal Patch Abuse and Accidental Pediatric Exposure Will Be Presented At the 2024 American Academy of Pain Medicine Annual Meeting	Mar. 04	CI
Nutriband Signs Agreement With Kindeva Drug Delivery for Aversa Fentanyl	Jan. 05	MT
Nutriband Inc. Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch	Jan. 05	CI
Nutriband Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	Dec. 13	CI
Nutriband Introduces Kinesiology Tape With Heating, Cooling Features	Nov. 28	MT
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling	Nov. 28	CI
Nutriband Signs Supplier Deal With KT Tape	Nov. 08	MT
Nutriband Inc. Signs Supplier Agreement with KT Tape	Nov. 08	CI
Top Premarket Decliners	Nov. 07	MT
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-11	MT
Sector Update: Health Care	23-10-11	MT
Nutriband Says Buprenorphine Product Has Potential to Reach Up to $130 Million in Annual US Sales	23-10-11	MT
Nutriband Secures US Patent for Abuse Deterrent Transdermal Products	23-09-20	MT
Nutriband Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-11	CI
Nutriband Inc. Launches AI Tape Brand Direct- to Consumer Offerings	23-07-27	CI
Sector Update: Health Care Stocks Advancing Late Friday	23-07-14	MT
Sector Update: Health Care Stocks Higher Friday Afternoon	23-07-14	MT
Top Midday Gainers	23-07-14	MT
Nutriband Shares Rise 14% After Credit Line Increased to Fund Fentanyl Deterrent Tech	23-07-14	DJ
Nutriband Expands Credit Line For AVERSA Fentanyl to $5 Million	23-07-14	MT

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. The Company's development pipeline includes AVERSA Buprenorphine and AVERSA Methylphenidate. The Company is also developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. Its AVERSA Fentanyl is an abuse-deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse-deterrent technology to reduce the abuse and misuse of fentanyl patches. It is also exploring transdermal delivery of proteins and peptides such as exenatide for type 2 diabetes and follicle-stimulating hormone (FSH) for infertility.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-27 - Q1 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
NUTRIBAND INC.	+50.86%	36.96M
ABBOTT LABORATORIES	-3.43%	184B
MEDTRONIC PLC	-1.81%	107B
BECTON, DICKINSON AND COMPANY	-4.15%	67.52B
DEXCOM, INC.	+1.43%	50.06B
CENCORA, INC.	+11.60%	45.67B
HOYA CORPORATION	+3.15%	41B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.03%	26.73B
WEST PHARMACEUTICAL SERVICES, INC.	+3.21%	26.47B
TERUMO CORPORATION	+15.62%	25.05B